Kainos Laboratories

Kainos Laboratories Net Margin

Delisted

The Net Profit Margin of Kainos Laboratories (4556.T) as of Oct 29, 2026 is 12.08 %. In the previous year, Net Profit Margin was 12.62 % — a change of -4.24% (lower).

Net Margin

12.08 %

YoY

-4.24%

Last updated:

Net Profit Margin of Kainos Laboratories is 2025 12.08 % . Net Profit Margin of Kainos Laboratories was 2024 12.62 % . It decreases by -4.24% lower compared to the previous year.

Kainos Laboratories's net margin stands at 12.1%, up from 9.8% several years earlier.

The Kainos Laboratories Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
6.34 JPY
Jan 1, 2019
8.26 JPY
Jan 1, 2020
8.65 JPY
Jan 1, 2021
9.80 JPY
Jan 1, 2022
11.10 JPY
Jan 1, 2023
11.54 JPY
Jan 1, 2024
12.62 JPY
Jan 1, 2025
12.08 JPY
The Kainos Laboratories Net Margin history
YEARNet MarginYoY
12.08 %-4.24%
12.62 %+9.33%
11.54 %+3.95%
11.10 %+13.25%
9.80 %+13.37%
8.65 %+4.64%
8.26 %+30.42%
6.34 %-3.82%
6.59 %+18.83%
5.54 %+31.84%
4.20 %+26.43%
3.33 %+11,723.37%
0.03 %+20.88%
0.02 %+43.47%
0.02 %-32.57%
0.02 %-48.43%
0.05 %+4,298.15%
0.00-71.20%
0.00-92.68%
0.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

Net Profit Margin of Kainos Laboratories is 12.08 % in 2025.

Net Profit Margin of Kainos Laboratories changed from 12.62 % to 12.08 %, representing a -4.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Kainos Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Kainos Laboratories

All Key Metrics — Kainos Laboratories